APA (7th ed.) Citation

Griffith, D. E., Eagle, G., Thomson, R., Aksamit, T. R., Hasegawa, N., Morimoto, K., . . . Winthrop, K. L. (2018). Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. American journal of respiratory and critical care medicine, 198(12), 1559-1569. https://doi.org/10.1164/rccm.201807-1318OC

Chicago Style (17th ed.) Citation

Griffith, David E., et al. "Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium Avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study." American Journal of Respiratory and Critical Care Medicine 198, no. 12 (2018): 1559-1569. https://doi.org/10.1164/rccm.201807-1318OC.

MLA (9th ed.) Citation

Griffith, David E., et al. "Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium Avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study." American Journal of Respiratory and Critical Care Medicine, vol. 198, no. 12, 2018, pp. 1559-1569, https://doi.org/10.1164/rccm.201807-1318OC.